[Quick Take] Interview with Tom Bjerg Lauritzen, President & CEO of Vivostat

The Vivostat System is an automated system for the on-site preparation and application of patient-derived fibrin sealant or platelet rich fibrin (PRF). It incorporates a unique biochemical process that produces an autologous sealant from 120 ml of the patient’s own blood in 23 minutes. The sealant has biophysical properties that outperform most sealants on the market today and a delivery system that enables precise control in the application during surgery.

Vivostat A/S is a privately owned company based in Scandinavia. The company’s products are sold through direct sales channels and distributors throughout Europe and Asia with the main focus on the cardiac, thoracic and hepatic surgery markets.

The comments are closed.